Last reviewed · How we verify

NCT05907902: AT-SUITABLE

Aspirin Treatment for Small Unruptured InTracranial Aneurysms With Ischemic cereBrovascuLar diseasE

Status unknown Phase 3 Last updated 18 June 2023
What this trial tests

Phase 3 trial testing Aspirin Enteric-coated Tablets in Intracranial Aneurysm in 824 participants. Status unknown.

Timeline
1 July 2023
Primary endpoint
1 July 2025
1 July 2025

Quick facts

Lead sponsorBeijing Tiantan Hospital
PhasePhase 3
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment824
Start date1 July 2023
Primary completion1 July 2025
Estimated completion1 July 2025
Sites2 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Tiantan Hospital

Who can join

Adults 18 to 80, any sex, with Intracranial Aneurysm or Cerebrovascular Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The management of small unruptured intracranial aneurysms (UIA) with ischemic cerebrovascular disease (ICVD) has been a very controversial topic in neurosurgery. Thus, we initiated a multicenter, prospective, randomized controlled trial (PROBE) design to elucidate in UIA patients with ICVD who do not qualify for preventive endovascular or neurosurgical intervention whether aspirin treatment decreases the risk of aneurysm growth and rupture.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Aspirin Enteric-coated Tablets

Trials testing the same drug.

Other recruiting trials for Intracranial Aneurysm

Currently open trials in the same condition.

Other Beijing Tiantan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05907902.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing